Among these agents, Trametinib has the greatest affinity for the MEK1/2 allosteric site, and has been approved for advanced NSCLC patients with BRAFV600E mutation in combination with Dabrafenib3,30. Here, MAP2K1 is linked to non-small cell lung carcinoma.